Should You Buy Hims & Hers Health, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Hims & Hers Health, Inc. (HIMS) is rated as a strong fundamental performer with a QOC score of 7.8/10. Trading at $27.85, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 0 of 8 CirclFi valuation models project upside for Hims & Hers Health, Inc. (HIMS) at $27.85 — the model consensus leans bearish, with a Quality Score of 7.8/10 and Value-Trap risk of 31/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Hims & Hers Health, Inc. (HIMS) in 2026?
What Is the Bull Case vs the Bear Case for Hims & Hers Health, Inc. (HIMS)?
| Bull case | Bear case — $2.64 target (-90.5%) |
|---|---|
| No active model projects meaningful upside for HIMS at $27.85. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $2.64 (-90.5%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry headwind: drug pricing legislation represents a meaningful risk for Hims & Hers Health, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does HIMS Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: XERS · PCRX · ORGO · CRON · KNSA · TRLV · EOLS · NTRR · CTTH · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like HIMS on Quality?
Closest companies to HIMS’s Quality of Company score of 7.8/10, across all industries.
- LEGH — Legacy Housing Corporation (QOC 7.8) · analysis
- LI — Li Auto Inc. (QOC 7.8) · analysis
- TRU — TransUnion (QOC 7.8) · analysis
- BORR — Borr Drilling Limited (QOC 7.8) · analysis
- SF — Stifel Financial Corp. (QOC 7.8) · analysis
- NWG — NatWest Group plc (QOC 7.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does HIMS Appear In?
So Is Hims & Hers Health, Inc. (HIMS) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Hims & Hers Health, Inc. at $27.85. 8/8 models flag overvaluation, median fair value sits at $5.53 (-80.1%), and the risk-reward profile appears unfavorable. Quality at 7.8/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Hims & Hers Health, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About HIMS Stock?
Should I buy HIMS stock right now?
Based on CirclFi's multi-model analysis, 0 of 8 models see upside for HIMS at $27.85. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Hims & Hers Health, Inc.?
Key risks include: wide model disagreement (232% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does HIMS compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, HIMS holds a Quality Score of 7.8/10. Comparable companies include XERS (QOC 7.9), PCRX (QOC 7.8), ORGO (QOC 8.0). The relative ranking helps investors identify whether HIMS offers better fundamental quality than alternatives in the same sector.
Is HIMS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. HIMS's Quality Score of 7.8/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy HIMS at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $2.64 to $8.78. At $27.85, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for HIMS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad